Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Conmed (CNMD) EPS (Weighted Average and Diluted) (2016 - 2026)

Conmed filings provide 17 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.45 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 136.84% to $0.45 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.77, a 53.42% decrease, with the full-year FY2025 number at $1.51, down 64.47% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.45 in Q1 2026 for Conmed, down from $0.54 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.57 in Q3 2024 to a low of -$5.65 in Q2 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.54 (2025), compared with a mean of $0.32.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 1478.05% in 2022 and later soared 950.0% in 2024.
  • Conmed's EPS (Weighted Average and Diluted) stood at $0.91 in 2022, then grew by 15.38% to $1.05 in 2023, then grew by 2.86% to $1.08 in 2024, then crashed by 50.0% to $0.54 in 2025, then dropped by 16.67% to $0.45 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.45 (Q1 2026), $0.54 (Q4 2025), and $0.09 (Q3 2025) per Business Quant data.